Zhejiang Sunflower Great Health Co Ltd

Zhejiang Sunflower Great Health Co Ltd has a strong liquidity position, with a current ratio of 6.23, indicating that it holds significantly more current assets than current liabilities. The company's cash and equivalents amount to CNY 37.4 million, and its free cash flow for the period is CNY 1.6 million, suggesting that it is generating positive cash from operations after capital expenditures. The company's profitability metrics are weak, with a negative return on equity of -0.64% and a return on assets of -0.45%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The operating income is negative at CNY -5.4 million, and the net income is also negative at CNY -4.4 million. Zhejiang Sunflower Great Health Co Ltd's revenue is primarily derived from its pharmaceutical products, with no disclosed segment breakdown. The company's geographic exposure is concentrated in China, as it is a domestic Chinese firm with no reported international operations. The company's growth trajectory is uncertain, as it has reported a decline in profitability. The operating and net income figures are negative, and there is no indication of a reversal in the near term. The company's capital expenditures were CNY -9.8 million, suggesting a reduction in investment in new projects or facilities. The company's risk profile is low in terms of liquidity and dilution. It has no immediate filing-based liquidity or dilution flags, and its debt-to-equity ratio is 0.0, indicating that it is not leveraged. The company's low dilution risk is further supported by the fact that its basic and diluted shares outstanding are the same, suggesting no imminent share issuance. There are no recent events or filings that indicate significant changes in the company's operations or financial position. The company's financial statements do not show any material developments in the form of new product launches, regulatory changes, or major business decisions.